MaxCyte Director Executes Stock Options and Sells Shares
MaxCyte Expands Share Capital, Fuels Cell Therapy Growth
TD Cowen Reaffirms Their Buy Rating on MaxCyte (MXCT)
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
BlackRock Ups Stake in MaxCyte to 9.75%
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $MaxCyte(MXCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.0% and a total average return of -4.6% over the past
Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Signing of Strategic Platform License
MaxCyte Signs Strategic Platform License With Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
MaxCyte Director Executes Stock Options and Sells
MaxCyte (LON:MXCT) Shareholders Have Earned a 22% CAGR Over the Last Five Years
Express News | MaxCyte Inc: Confident We Will Deliver Our Full Year Guidance
Earnings Flash (MXCT.L) MAXCYTE Reports H1 Loss $-0.18
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating
TD Cowen analyst Steven Mah maintains $MaxCyte(MXCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 27.4% and a total average return of -10.9% over the past year.
Buy Rating Affirmed for MaxCyte on Strong SPL Revenue Growth and Solid Financial Position
MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript
MaxCyte GAAP EPS of -$0.09 Beats by $0.04, Revenue of $10.4M Beats by $2.47M
MaxCyte Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results.
MaxCyte | 10-Q: Quarterly report
Express News | MaxCyte Inc -Qtrly Loss per Share $0.09